Kane Biotech Inc. (KNBIF)
OTCMKTS
· Delayed Price · Currency is USD
0.0371
0.00 (0.00%)
Jun 11, 2025, 8:00 PM EDT
Kane Biotech Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 2.44 | 2.08 | 0.15 | 0.16 | 1.61 | 1.34 | Upgrade
|
| Revenue Growth (YoY) | 1374.38% | 1296.75% | -4.95% | -90.25% | 19.84% | -20.78% | Upgrade
|
| Cost of Revenue | 1.57 | 1.21 | 0.04 | 0.04 | 1.04 | 0.81 | Upgrade
|
| Gross Profit | 0.87 | 0.87 | 0.11 | 0.11 | 0.57 | 0.53 | Upgrade
|
| Selling, General & Admin | 3.23 | 3.08 | 2.41 | 2.53 | 4.07 | 3.43 | Upgrade
|
| Research & Development | 1.33 | 1.51 | 1.05 | 1.04 | 1.31 | 1.29 | Upgrade
|
| Operating Expenses | 4.57 | 4.59 | 3.46 | 3.57 | 5.39 | 4.71 | Upgrade
|
| Operating Income | -3.69 | -3.72 | -3.35 | -3.46 | -4.82 | -4.18 | Upgrade
|
| Interest Expense | -0.29 | -0.55 | -1.22 | -0.82 | -0.42 | -0.12 | Upgrade
|
| Interest & Investment Income | 0.01 | 0 | 0.01 | 0.02 | 0.12 | 0.04 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.02 | -0.01 | 0 | -0.02 | 0 | 0 | Upgrade
|
| EBT Excluding Unusual Items | -3.99 | -4.27 | -4.56 | -4.28 | -5.11 | -4.27 | Upgrade
|
| Asset Writedown | -0.21 | -0.21 | -0.01 | - | -0.07 | -0.04 | Upgrade
|
| Other Unusual Items | - | - | 0 | 0.25 | 0.32 | 0.46 | Upgrade
|
| Pretax Income | -4.2 | -4.47 | -4.56 | -4.02 | -4.85 | -3.85 | Upgrade
|
| Income Tax Expense | -1.31 | -1.31 | - | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -2.89 | -3.16 | -4.56 | -4.02 | -4.85 | -3.85 | Upgrade
|
| Earnings From Discontinued Operations | 9.16 | 9.26 | -0.47 | 0.13 | - | - | Upgrade
|
| Net Income to Company | 6.28 | 6.1 | -5.03 | -3.89 | -4.85 | -3.85 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | 0.25 | 0.13 | Upgrade
|
| Net Income | 6.28 | 6.1 | -5.03 | -3.89 | -4.6 | -3.72 | Upgrade
|
| Net Income to Common | 6.28 | 6.1 | -5.03 | -3.89 | -4.6 | -3.72 | Upgrade
|
| Shares Outstanding (Basic) | 138 | 134 | 127 | 121 | 113 | 109 | Upgrade
|
| Shares Outstanding (Diluted) | 160 | 155 | 127 | 121 | 113 | 109 | Upgrade
|
| Shares Change (YoY) | 24.10% | 22.23% | 5.32% | 7.20% | 3.67% | 31.97% | Upgrade
|
| EPS (Basic) | 0.05 | 0.05 | -0.04 | -0.03 | -0.04 | -0.03 | Upgrade
|
| EPS (Diluted) | 0.05 | 0.05 | -0.04 | -0.03 | -0.04 | -0.03 | Upgrade
|
| Free Cash Flow | -4.26 | -4.14 | -2.09 | -3.05 | -2.48 | -3.97 | Upgrade
|
| Free Cash Flow Per Share | -0.03 | -0.03 | -0.02 | -0.03 | -0.02 | -0.04 | Upgrade
|
| Gross Margin | 35.82% | 41.91% | 73.48% | 71.48% | 35.36% | 39.27% | Upgrade
|
| Operating Margin | -151.16% | -178.66% | -2248.93% | -2206.05% | -299.63% | -311.93% | Upgrade
|
| Profit Margin | 257.02% | 293.05% | -3379.05% | -2481.86% | -286.39% | -277.04% | Upgrade
|
| Free Cash Flow Margin | -174.66% | -198.77% | -1403.79% | -1947.70% | -153.99% | -295.64% | Upgrade
|
| EBITDA | -3.63 | -3.62 | -3.23 | -3.3 | -4.73 | -4.12 | Upgrade
|
| EBITDA Margin | -148.75% | -174.05% | - | - | -294.36% | - | Upgrade
|
| D&A For EBITDA | 0.06 | 0.1 | 0.12 | 0.16 | 0.08 | 0.07 | Upgrade
|
| EBIT | -3.69 | -3.72 | -3.35 | -3.46 | -4.82 | -4.18 | Upgrade
|
| EBIT Margin | -151.16% | -178.66% | - | - | -299.63% | - | Upgrade
|
| Revenue as Reported | 2.44 | 2.08 | 0.15 | 0.16 | 1.61 | 1.34 | Upgrade
|
Updated Nov 28, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.